ATyr Pharma Analyst Ratings
ATyr Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/21/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
09/14/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
08/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
07/21/2023 | 1134.57% | Piper Sandler | $13 → $20 | Maintains | Overweight |
07/05/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
05/23/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | Buy → Buy |
05/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
04/11/2023 | 702.47% | Piper Sandler | $9 → $13 | Maintains | Overweight |
03/10/2023 | 1072.84% | RBC Capital | → $19 | Reiterates | → Outperform |
03/10/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
03/06/2023 | 455.56% | Roth MKM | → $9 | Reinstates | → Buy |
03/02/2023 | 1072.84% | RBC Capital | $20 → $19 | Maintains | Outperform |
02/07/2023 | 2060.49% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
08/16/2022 | 764.2% | Piper Sandler | $11 → $14 | Maintains | Overweight |
07/21/2022 | 2060.49% | HC Wainwright & Co. | $11 → $35 | Maintains | Buy |
05/18/2022 | 579.01% | Piper Sandler | $19 → $11 | Maintains | Overweight |
05/10/2022 | 1134.57% | RBC Capital | $22 → $20 | Maintains | Outperform |
11/11/2021 | 579.01% | HC Wainwright & Co. | $18 → $11 | Maintains | Buy |
10/12/2021 | 1258.02% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
09/21/2021 | 1072.84% | Piper Sandler | → $19 | Initiates Coverage On | → Overweight |
09/14/2021 | 1196.3% | Roth Capital | $20 → $21 | Maintains | Buy |
09/14/2021 | 1134.57% | Oppenheimer | $14 → $20 | Maintains | Outperform |
09/13/2021 | 1011.11% | HC Wainwright & Co. | $13 → $18 | Maintains | Buy |
05/18/2021 | 825.93% | JonesTrading | → $15 | Initiates Coverage On | → Buy |
03/24/2021 | 764.2% | Oppenheimer | $12 → $14 | Maintains | Outperform |
03/16/2021 | 1134.57% | Roth Capital | $15 → $20 | Maintains | Buy |
08/17/2020 | 702.47% | HC Wainwright & Co. | → $13 | Upgrades | Neutral → Buy |
03/27/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
03/02/2020 | 393.83% | Oppenheimer | → $8 | Initiates Coverage On | → Outperform |
11/05/2019 | 393.83% | HC Wainwright & Co. | → $8 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年09月21日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 购买→购买 |
09/14/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 购买→购买 |
2023年08月10日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 购买→购买 |
07/21/2023 | 1134.57% | 派珀·桑德勒 | $13→$20 | 维护 | 超重 |
07/05/2023 | - | 奥本海默 | 评级下调 | 超越→表现 | |
2023年05月23日 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | 购买→购买 |
2023年05月10日 | 1072.84% | 加拿大皇家银行资本 | →$19 | 重申 | →跑赢大盘 |
04/11/2023 | 702.47% | 派珀·桑德勒 | $9→$13 | 维护 | 超重 |
03/10/2023 | 1072.84% | 加拿大皇家银行资本 | →$19 | 重申 | →跑赢大盘 |
03/10/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | →购买 |
03/06/2023 | 455.56% | 罗斯MKM | →$9 | 恢复 | →购买 |
03/02/2023 | 1072.84% | 加拿大皇家银行资本 | $20→$19 | 维护 | 跑赢大盘 |
02/07/2023 | 2060.49% | HC Wainwright公司 | →$35 | 重申 | →购买 |
08/16/2022 | 764.2% | 派珀·桑德勒 | $11→$14 | 维护 | 超重 |
07/21/2022 | 2060.49% | HC Wainwright公司 | $11→$35 | 维护 | 买 |
2022/05/18 | 579.01% | 派珀·桑德勒 | $19→$11 | 维护 | 超重 |
2022年05月10日 | 1134.57% | 加拿大皇家银行资本 | $22→$20 | 维护 | 跑赢大盘 |
2021年11月11日 | 579.01% | HC Wainwright公司 | $18→$11 | 维护 | 买 |
10/12/2021 | 1258.02% | 加拿大皇家银行资本 | →$22 | 开始承保 | →跑赢大盘 |
2021/09/21 | 1072.84% | 派珀·桑德勒 | →$19 | 开始承保 | →超重 |
09/14/2021 | 1196.3% | 罗斯资本 | $20→$21 | 维护 | 买 |
09/14/2021 | 1134.57% | 奥本海默 | $14→$20 | 维护 | 跑赢大盘 |
09/13/2021 | 1011.11% | HC Wainwright公司 | $13→$18 | 维护 | 买 |
2021/05/18 | 825.93% | Jones Trading | →$15 | 开始承保 | →购买 |
03/24/2021 | 764.2% | 奥本海默 | $12→$14 | 维护 | 跑赢大盘 |
03/16/2021 | 1134.57% | 罗斯资本 | $15→$20 | 维护 | 买 |
2020/08/17 | 702.47% | HC Wainwright公司 | →$13 | 升级 | 中性→购买 |
03/27/2020 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
03/02/2020 | 393.83% | 奥本海默 | →$8 | 开始承保 | →跑赢大盘 |
2019年11月05日 | 393.83% | HC Wainwright公司 | →$8 | 开始承保 | →购买 |
What is the target price for aTyr Pharma (LIFE)?
ATyr Pharma(LIFE)的目标价是多少?
The latest price target for aTyr Pharma (NASDAQ: LIFE) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $35.00 expecting LIFE to rise to within 12 months (a possible 2060.49% upside). 13 analyst firms have reported ratings in the last year.
纳斯达克(纳斯达克代码:LIFE)的最新目标价是由HC Wainwright&Co.于2023年9月21日报道的。这家分析公司将目标价格定为35美元,预计寿命将在12个月内上升(可能上涨2060.49%)。过去一年,有13家分析公司公布了评级。
What is the most recent analyst rating for aTyr Pharma (LIFE)?
分析师对aTyr Pharma(LIFE)的最新评级是多少?
The latest analyst rating for aTyr Pharma (NASDAQ: LIFE) was provided by HC Wainwright & Co., and aTyr Pharma reiterated their buy rating.
分析师对aTyr Pharma(纳斯达克代码:LIFE)的最新评级由HC Wainwright&Co.提供,aTyr Pharma重申其买入评级。
When is the next analyst rating going to be posted or updated for aTyr Pharma (LIFE)?
ATyr Pharma(LIFE)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of aTyr Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for aTyr Pharma was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与aTyr Pharma的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。ATyr Pharma的上一次评级是在2023年9月21日提交的,所以你应该预计下一次评级将在2024年9月21日左右的某个时候提供。
Is the Analyst Rating aTyr Pharma (LIFE) correct?
分析师对aTyr Pharma(LIFE)的评级正确吗?
While ratings are subjective and will change, the latest aTyr Pharma (LIFE) rating was a reiterated with a price target of $0.00 to $35.00. The current price aTyr Pharma (LIFE) is trading at is $1.62, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的aTyr Pharma(LIFE)评级被重申,目标价在0.00美元至35.00美元之间。目前aTyr Pharma(LIFE)的交易价格为1.62美元,在分析师的预测范围内。